The Firm is representing Amneal Pharmaceuticals, Inc. (“Amneal”) in connection with its announced agreement to acquire Kashiv BioSciences, LLC (“Kashiv”) in a transaction with consideration that includes $375 million of cash and $375 million of Amneal stock, plus up to $350 million in potential payments based on the achievement of certain regulatory milestones, and potential royalties based on certain commercial milestones. The transaction is expected to close in the second half of 2026, subject to approval by Amneal’s shareholders, regulatory approvals and customary closing conditions.
Amneal, headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal has a portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States.
Kashiv is a vertically integrated biopharmaceutical company with commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars.
The Simpson Thacher team includes Jakob Rendtorff, Benjamin Bodurian, Dan Kim, Derrick Ray, Daniel Song and Andrés Cruz (M&A); Richard Fenyes (Corporate); Vanessa Burrows, Alison Peters and Jacob Madden (Healthcare); Andrew Purcell and Shareef Salfity (Tax); Jamin Koslowe, Ashlie Lawton, Josh Goldman and Marie Gesellschap (Executive Compensation & Employee Benefits); Alysha Sekhon and Christian Bond (Intellectual Property); Karen Hsu Kelley and Brandon Adoni (Public Company Advisory Practice); Mark Skerry, Austin Lowe and Feven Yohannes (FDI); Peter Guryan and Allison Davido (Antitrust); Carleigh Rodriguez and Erin Magoffie (Environmental); Krista McManus (Real Estate); Abram Ellis, Christine Tillema and Brian Japari (Regulatory); Steven DeLott (Insurance); and Leah Malone and Chayla Sherrod (Sustainability & ESG).